Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/24/2903035/0/en/SELLAS-Announces-U-S-FDA-Rare-Pediatric-Disease-Designation-Granted-to-SLS009-for-the-Treatment-of-Pediatric-Acute-Lymphoblastic-Leukemia.html
https://www.globenewswire.com/news-release/2024/06/17/2899713/0/en/SELLAS-Life-Sciences-Announces-Positive-Recommendation-from-the-Independent-Data-Monitoring-Committee-of-the-Phase-3-REGAL-Trial-in-Acute-Myeloid-Leukemia.html
https://www.globenewswire.com/news-release/2024/06/10/2896012/0/en/SELLAS-Announces-Completion-of-Enrollment-and-Initial-Positive-Data-in-Phase-2a-Trial-of-SLS009-in-r-r-AML.html
https://www.globenewswire.com/news-release/2024/05/14/2881857/0/en/SELLAS-Life-Sciences-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/01/2873258/0/en/SELLAS-Announces-Positive-Phase-2-Preliminary-Data-of-SLS009-in-r-r-AML-Achieving-a-100-Response-Rate-in-Patients-with-ASXL1-Mutation-At-the-Optimal-Dose-Level.html
https://www.globenewswire.com/news-release/2024/04/29/2871255/0/en/SELLAS-Life-Sciences-Announces-Positive-Recommendation-of-Independent-Data-Monitoring-Committee-Following-Completion-of-Enrollment-in-REGAL-Phase-3-Study.html
https://www.globenewswire.com/news-release/2024/03/28/2854454/0/en/SELLAS-Life-Sciences-Reports-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/03/26/2852262/0/en/SELLAS-Announces-Positive-Topline-Data-from-the-Phase-2a-Study-of-SLS009-in-r-r-AML-and-Provides-Steering-Committee-Update-on-Phase-3-REGAL-Study.html
https://www.globenewswire.com/news-release/2024/03/19/2848962/0/en/SELLAS-Life-Sciences-Group-Announces-Closing-of-20-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html